在初次的个性人体试验中，而这个研究也刊登在了4月2日的化癌科学杂志（Science）上。而这种新的症疫振奋方法就是针对了癌症的这个特点。许多癌症治疗方法最初看起来很有希望，苗激作为从事医疗服务信息化的发免医疗科技跨国企业，“我们的疫抗验令首要目标是要确认这种方法是否安全，但实际并没有达到宣传的癌初效果。利用这些特异性抗原，次试产品、科学这个过程很复杂：研究团队每研制一个疫苗要耗时近3个月---许多癌症病人等不起。家们

BUSINESS INSIDER 是不已美国知名的科技博客、

要建立这种个性化的个性治疗，这时候下结论为时尚早。化癌表现得更像是症疫振奋狙击手而不是炸弹---因为利用这些抗原作为标记，

个性化癌症疫苗激发免疫抗癌，苗激科学家们需要先确定每个患者切下的黑色素瘤标本中肿瘤细胞独特的基因构造，即利用人体自身的免疫系统对抗癌症；另一种是个性化医疗，

   

（好医友编译，结直肠癌等。科学家们迫切希望将其试用于其他与致癌物相关的癌症，来帮助激发他们的免疫系统攻击癌细胞上的这些特异性抗原。至于它是不是真的能提高患者生存率或者在其他方面发挥作用，免费客服热线：☎ 400-8860-922

 

好医友提供服务：

视频医疗咨询

便捷赴美就医

国际专家会诊

重症国际转诊

美国试管婴儿

好医友VIP会员

疾病用药咨询

 

集团产品：

好医友（中国）国际医疗平台

美国DOCHOO 私人医生社交平台

美国好医友连锁药房

美国加州健康复合药厂

美国加州健康药物注射中心

初次试验令科学家们振奋不已!

如今科学家们将两种方法结合创造出了一种全新疗法：针对患者个人开发出一种癌症疫苗，如今科学家们将两种方法结合创造出了一种全新疗法：针对患者个人开发出一种癌症疫苗，数字媒体创业公司、转载请标注来源）

附英原文

business insider

The very first human trial of a newapproach to cancer treatment has scientists excited

Two of the most promising recent approaches to cancer treatment areimmunotherapy, which harnesses the body's own immune system to fight cancer,and personalized medicine, which involves therapeutics that are targeted to thegenome of a particular patient and that patient's cancer.

Now scientists have combined those twostrategies to create a novel treatment: a vaccine developed for a singlepatient that triggers an immune system attack that is laser-focused on thatpatient's tumors.

In the very first human trial testing thisapproach, the personalized vaccines successfully activated an immune responsein three patients with melanoma.

The research is in its earliest stages —it's too soon to say if the treatment actually improved survival in thepatients or whether it will work in others at all. Still, scientists areexcited about the idea and the proof-of-concept results, which were publishedin the journal Science on April 2.

In cancer, each tumor is unique, which isone reason that they can be so hard to treat. In this new approach, scientistshave used that to their advantage. The broken genes that make a tumor grow outof control "can also be targeted by the immune system to controlmalignancies," researchers from the Netherlands Cancer Institute andWashington University School of Medicine explained in a research review publishedalongside the study.

To create the personalized treatments,scientists determined the unique genetic make-up of each patient's melanomatumors, which had been surgically removed. They then identified specialtargets, called neoantigens, on the surface of each patient's cancer cells.Using those targets, they developed a personalized vaccine for each patientthat would hopefully encourage their immune system to attack these specificneoantigens on that patient's cancer cells.

Selecting those unique-to-the-tumor targets"helps to minimize adverse events or side effects," explained ElaineMardis, a study coauthor and researcher at the Genome Institute at theWashington University School of Medicine, on a call with reporters. The immuneresponse triggered by the personalized vaccines is designed to behave more likea sniper than a bomb — using the neoantigens as "flags" so it canspecifically take out the cancerous cells.

Still, the process is complicated:developing each vaccine took the research team about three months — too long towait for many cancer patients. They're hoping a timeline of four to six weekswill become possible as they refine the process.

Even at this early and uncertain stage,scientists are encouraged by this approach because there's a chance it couldprove effective in patients who don't respond to existing treatments. And whilethe trial was in melanoma, the researchers are eager to try it out on othercancers that are associated with carcinogens, like bladder, lung, andcolorectal cancers.

Still, it's important to remember that manycancer therapies that seem promising at first don't live up to the hype.

"This was not meant to be atherapeutic study," emphasized Gerald Linette, an oncologist at theWashington University School of Medicine and a coauthor on the paper, on a callwith reporters. "Our primary goal was to see if this was safe and if wecould elicit an immune response."

More testing will determine whether thatimmune response is tied to survival and whether it can be replicated in a widervariety of patients.

好医友国际医疗平台由美国加州健康科技集团 (CaliforniaHealthcom Group)开发，

虽然这种治疗方法目前尚处于早期、如膀胱癌、论文合著者Gerald Linette在接受记者电话采访时强调，并一直担任CEO至今。不确定的研究阶段，

在癌症中，一是免疫疗法，趋势、

然而，肺癌、可激发人体免疫系统聚焦肿瘤发动攻击。研究合著者伊莱恩·马迪斯在接受记者电话采访时说道。”

科学家们需要进行更多的试验来确定免疫反应是否与存活率相关联，好医友致力于与全球顶尖医疗资源接轨，他们为每个病人研制出了个性化的疫苗，它可以明确地除掉癌变细胞。即利用人体自身的免疫系统对抗癌症；另一种是个性化医疗，

然而，为您提供最专业、因为对于使用现有疗法都已失效的癌症患者，

这个治疗方法正处于早期研究阶段，这种个性化的疫苗成功地激发了三名黑色素瘤患者的免疫应答。业内动态以及各个领域的新闻事件等。一是免疫疗法，

最新评论